The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Open accessAbstract
We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid leukemia (AML). A 41-year-old male patient with AML was enrolled and received a total of 1.12 × 10(9) autologous CART-33 cells, of which ~38% were transduced with CAR. The CART-33 infusion alone induced rigorous chills and fevers; drastic fluctuations of his preexisting pancytopenia; elevated serum cytokine levels, including interleukin (IL)-6, IL-8, tumor necrosis factor-α, and interferon-γ; slight transient hyperbilirubinemia within 2 weeks; a subsequent intermittent moderate fever; and reversed fluctuation of the pancytopenia. A marked decrease of blasts in the bone marrow was observed on examination 2 weeks after therapy, and there was a gradual increase until florid disease progression occurred at 9 weeks after the cell infusion. These observations warrant further research on CART-33 treatment in refractory AML and may spur efforts to extend the CART-33-induced tumor burden to the preparation of other intensive strategies, such as hematopoietic stem cell transplantation. This study is registered at www.ClinicalTrials.gov as NCT01864902.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Pizzitola, I., Anjos-Afonso, F., Rouault-Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 287
Pearce, D. J., Taussig, D., Zibara, K., Smith, L.-L., Ridler, C. M., Preudhomme, C., Young, B. D., Rohatiner, A. Z., Lister, T. A., & Bonnet, D. (2006) · Blood · doi:10.1182/blood-2005-06-2325 · Cited by 234
Expression of normal myeloid-associated antigens by acute leukemia cells
Dinndorf, P., Andrews, R., Benjamin, D., Ridgway, D., Wolff, L., & Bernstein, I. (1986) · Blood · doi:10.1182/blood.v67.4.1048.1048 · Cited by 229
Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J. A., Sega, E. I., Karimi, M., & Negrin, R. S. (2008) · Blood · doi:10.1182/blood-2007-06-092817 · Cited by 198
The past and future of CD33 as therapeutic target in acute myeloid leukemia
Laszlo, G. S., Estey, E. H., & Walter, R. B. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.04.001 · Cited by 192
McKoy, J. M., Angelotta, C., Bennett, C. L., Tallman, M. S., Wadleigh, M., Evens, A. M., Kuzel, T. M., Trifilio, S. M., Raisch, D. W., Kell, J., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.005 · Cited by 180
Clonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G., & Wu, C. J. (2014) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 164
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells
Hauswirth, A. W., Florian, S., Printz, D., Sotlar, K., Krauth, M. ‐., Fritsch, G., Schernthaner, G. ‐., Wacheck, V., Selzer, E., Sperr, W. R., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01746.x · Cited by 158
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
Hernández‐Caselles, T., Martinez‐Esparza, M., Pérez‐Oliva, A. B., Quintanilla-Cecconi, A. M., García-Alonso, A. M., Álvarez‐López, D. M. R., & García–Peñarrubia, P. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205096 · Cited by 141
Marin, V., Pizzitola, I., Agostoni, V., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.026310 · Cited by 132
Tumor heterogeneity makes AML a “moving target” for detection of residual disease
Zeijlemaker, W., Gratama, J. W., & Schuurhuis, G. J. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21134 · Cited by 127
Corradetti, M. N., Mitra, N., Millar, L. P. B., et al. (2012) · Practical Radiation Oncology · doi:10.1016/j.prro.2012.10.005 · Cited by 119
Dutour, A., Marin, V., Pizzitola, I., Valsesia‐Wittmann, S., Lee, D. A., Yvon, E. S., Finney, H. M., Lawson, A. D. G., Brenner, M. K., Biondi, A., et al. (2012) · Advances in Hematology · doi:10.1155/2012/683065 · Cited by 105
Cell Surface Antigen Expression in Human Erythroid Progenitors: Erythroid and Megakaryocytic Markers
Nakahata, T., & Okumura, N. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409049629 · Cited by 79
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
Walter, R. (2013) · Frontiers in bioscience · doi:10.2741/4181 · Cited by 65
Maniecki, M. B., Hasle, H., Bendix, K., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.01.025 · Cited by 26
Tettamanti, S., Magnani, C. F., Biondi, A., & Biagi, E. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.09.013 · Cited by 21
Cited by
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Metadata
- Authors
- Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 23
- Issue
- 1
- Pages
- 184-191
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2077994554
- Cited by
- 418
- References
- 29
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.